Patents by Inventor Jason Cantor

Jason Cantor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230051644
    Abstract: In some aspects, described herein are cell culture media that are useful for in vitro culture of mammalian cells. The culture media contain a variety of small organic compounds that are found in normal adult human blood. Also described are methods of using the culture media for a variety of purposes. Also described are methods of treating cancer.
    Type: Application
    Filed: August 4, 2022
    Publication date: February 16, 2023
    Inventors: David M. SABATINI, Jason Cantor
  • Patent number: 11453858
    Abstract: In some aspects, described herein are cell culture media that are useful for in vitro culture of mammalian cells. The culture media contain a variety of small organic compounds that are found in normal adult human blood. Also described are methods of using the culture media for a variety of purposes. Also described are methods of treating cancer.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: September 27, 2022
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: David M. Sabatini, Jason Cantor
  • Publication number: 20190352598
    Abstract: In some aspects, described herein are cell culture media that are useful for in vitro culture of mammalian cells. The culture media contain a variety of small organic compounds that are found in normal adult human blood. Also described are methods of using the culture media for a variety of purposes. Also described are methods of treating cancer.
    Type: Application
    Filed: November 13, 2017
    Publication date: November 21, 2019
    Inventors: David M. Sabatini, Jason Cantor
  • Publication number: 20120148559
    Abstract: The invention provides deimmunized mutant proteins having reduced immunogenicity while exhibiting substantially the same or greater biological activity as the proteins of interst from which they are derived, as exemplified by mutant L-asparaginase that comprises amino acid substitutions compared to wild type L-asparaginase. The invention further provides methods for screening mutant deimmunized proteins that have substantially the same or greater biological activity as a protein of interest, and methods for reducing immunogenicity, without substantially reducing biological activity, of a protein of interest. The invention's compositions and methods are useful in, for example, therapeutic applications by minimizing adverse immune responses by the host mammalian subjects to the protein of interest.
    Type: Application
    Filed: November 30, 2011
    Publication date: June 14, 2012
    Applicant: Board of Regents The University of Texas System
    Inventors: George Georgiou, Jason Cantor, Tae Hyeon Yoo